Locations:

Tag: mavacamten

22-HVI-2769712_hyptertrophic-cardiomyopathy_650x450

April 5, 2022/Heart, Vascular and Thoracic/Clinical Cardiology

Mavacamten Significantly Reduces Patients’ Need for Septal Reduction Therapy Over 16 Weeks

Longer-term confirmation of VALOR-HCM could yield a noninvasive therapy for severe obstructive HCM

cardiac magnetic resonance images showing hypertrophic cardiomyopathy

March 9, 2020/Heart, Vascular and Thoracic/Research

Hypertrophic Cardiomyopathy: Signs of Progress Toward a Medical Therapy and Refined Risk Prediction

New and ongoing studies aim to reduce the need for surgery, improve risk stratification

BackPage 2 of 2Next

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy